Facebook-f Linkedin-in

China private CNS developer seeking to enter U.S. market

Tags

China to US
Private
CNS
US market entry
Clinical stage

Overview

A private biotech firm in China was developing a phase 3 asset targeting Central Nervous System disorders.

The company engaged Treehill to expand partnerships and further build out long-term development strategies to maximize asset value.

Situation and Challenges

Having reached the stage of having a stage 3 asset under development, the firm now needed to expand partnerships, especially with international players.

To achieve this, the company needed to further evolve their longer-term development strategies.

Treehill Solution

Evaluated the appropriate target markets for the asset beyond the initial indication.

Assessed the feasibility of a potential partnering transaction for the asset.

Enhanced the transactability of this firm’s assets by enhancing their regulatory and pre-commercial positions.

Evaluated the suitability and potential of employing a NewCo strategy.

Conclusion and Outcome

  • Long-term development strategy for the asset across multitude of indications
  • Discussions with large pools of multi-national corporations

Evaluated the appropriate target markets for the asset beyond the initial indication.

Assessed the feasibility of a potential partnering transaction for the asset.

Assessed the feasibility of a potential partnering transaction for the asset.

Assessed the feasibility of a potential partnering transaction for the asset.

The company selected Treehill Partners specifically for expertise in viewing the asset with the eyes of a potential investor. Treehill:

Evaluated the appropriate target markets for the asset beyond the initial indication.

Assessed the feasibility of a potential partnering transaction for the asset.

Enhanced the transactability of this firm’s assets by enhancing their regulatory and pre-commercial positions.

Evaluated the suitability and potential of employing a NewCo strategy.